Vaxrevia DATA RELEASE - 2
By March 2021, MHRA had received 15,146 reports of cardiovascular events and 1,014 reports of thromboembolic events.
In our first post, we told the story of our quest for evidence of harms following vaccination with the Covid-19 AstraZeneca Vaccine (AZD1222/ChAdOx1-S), since christened Vaxrevia.
In this post, we analyse what more can be said of the information we obtained from the UK’s MHRA.
To the best of our knowledge, this is the first time anyone (outside the powerful) has seen the reports submitted to the MHRA regarding serious potential harms during the first period of the rollout of British Science’s triumph.
Here are the 48,472 reports for cardiac disorders following vaccination by month of reporting:
Here are the data for thromboembolic effects:
